Cite
MLA Citation
S. Sadeghi et al.. “Phase II California Cancer Consortium trial of gemcitabine–eribulin combination (GE) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): tolerability and toxicity report (NCI-9653; 1UM1CA186717-01, NO1-CM-2011-00038).” European journal of cancer, vol. 72, n.d., pp. S197–. http://access.bl.uk/ark:/81055/vdc_100041522304.0x00005e